Cardiac ablation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:48 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cardiac ablation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Long-Term Anticoagulation with Rivaroxaban vs. Acetylsalicylic Acid for Patients at Risk of Stroke After Atrial Fibrillation Ablation https://clinicaltrials.eu/trial/study-on-long-term-anticoagulation-with-rivaroxaban-vs-acetylsalicylic-acid-for-patients-at-risk-of-stroke-after-atrial-fibrillation-ablation/ Wed, 29 Apr 2026 14:57:37 +0000 https://clinicaltrials.eu/trial/study-on-long-term-anticoagulation-with-rivaroxaban-vs-acetylsalicylic-acid-for-patients-at-risk-of-stroke-after-atrial-fibrillation-ablation/ This clinical trial is focused on patients who have undergone a procedure called catheter ablation to treat atrial fibrillation, a condition that can increase the risk of having a stroke. The study is investigating two different treatments to see which is more effective in reducing the risk of stroke and other related events. The first treatment involves the use of a medication called rivaroxaban, which is a type of blood thinner that helps prevent blood clots. The second treatment uses acetylsalicylic acid, commonly known as aspirin, which is also used to prevent blood clots but works in a different way.

The purpose of the study is to determine whether continuing long-term treatment with rivaroxaban is better than using acetylsalicylic acid alone in preventing strokes and other similar events in patients who are at moderate risk after their successful catheter ablation. Participants in the study will be randomly assigned to receive either rivaroxaban or acetylsalicylic acid. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients. The study will last for up to 36 months, during which time participants will have regular check-ups and tests to monitor their health and the effects of the treatment.

The main goal is to see if there is a difference in the occurrence of strokes or other related events between the two treatment groups. The study will also look at other outcomes, such as the occurrence of bleeding, changes in brain scans using MRI, and overall quality of life. This information will help doctors understand the best way to prevent strokes in patients who have had atrial fibrillation and have undergone catheter ablation.

]]> Study on Early Treatment of Persistent Atrial Fibrillation: Comparing Cryoballoon Therapy with Dronedarone, Flecainide, Sotalol, and Propafenone in Symptomatic Patients https://clinicaltrials.eu/trial/study-on-early-treatment-of-persistent-atrial-fibrillation-comparing-cryoballoon-therapy-with-dronedarone-flecainide-sotalol-and-propafenone-in-symptomatic-patients/ Wed, 29 Apr 2026 14:23:59 +0000 https://clinicaltrials.eu/trial/study-on-early-treatment-of-persistent-atrial-fibrillation-comparing-cryoballoon-therapy-with-dronedarone-flecainide-sotalol-and-propafenone-in-symptomatic-patients/ This clinical trial is focused on studying the treatment of Persistent Atrial Fibrillation (AF), a condition where the heart beats irregularly and often rapidly. The study compares two different approaches to managing this condition. One approach involves a procedure called cryoablation, which uses a special tool called a Cryoballoon to freeze and isolate the areas of the heart that trigger AF. The other approach uses medications known as antiarrhythmic drugs (AAD) to help control the heart’s rhythm. The medications being studied include Dronedarone, Flecainide, Sotalol, and Propafenone.

The purpose of the study is to determine if early treatment with cryoablation is more effective than using antiarrhythmic drugs in preventing the recurrence of irregular heartbeats. Participants in the study will be randomly assigned to receive either the cryoablation procedure or one of the antiarrhythmic medications. The study will monitor participants over a period of time to see how well each treatment works in reducing episodes of irregular heartbeats and improving overall heart health.

Throughout the study, participants will have regular check-ups to assess their heart rhythm and overall health. The study aims to provide valuable information on the best first-line treatment strategy for managing Persistent Atrial Fibrillation, potentially leading to improved outcomes for patients with this condition. The study will also look at other factors such as healthcare costs, quality of life, and any side effects related to the treatments.

]]>